HopeStage
Back to all studies
CompletedNCT04944017

Ketamine studied for depression in Parkinson’s disease

About this titleRead the official source — NCT04944017

This study assessed depression symptoms.

Medication studyAges 40–80United States
The study in practice

Understand this study

What did researchers investigate?

This study assessed depression symptoms.

Who was this study for?

This study was for people with depression. Listed age limits: 40 years to 80 years. Other eligibility criteria applied.

Listed locations
New HavenSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 23, 2021
Recruitment status
Completed
Enrollment listed in the registry
51
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 40 Years to 80 Years
Official registry ID
NCT04944017
Official title
Show the full official title

Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study assessed depression symptoms.

Who is behind this study?

The study sponsor is Yale University, a university.

Did this study involve medication?

Yes. The study involved medication, including Ketamine Infusion.

Who was this study for?

This study was for people with depression. Listed age limits: 40 years to 80 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies